Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
| Autor: | Mardi Gomberg-Maitland, Aaron B. Waxman, Marty Morris, Jeffrey A. Murphy, Shelley M. Shapiro, Amy A Lautenbach, Robert C. Bourge, Jeremy Feldman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty medicine.medical_treatment internal device Patient characteristics Case Report 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Chart review medicine Lung transplantation Saline lcsh:RC705-779 Lung business.industry prostacyclin treprostinil lcsh:Diseases of the respiratory system Surgery Transplantation Catheter medicine.anatomical_structure 030228 respiratory system lcsh:RC666-701 business Treprostinil medicine.drug |
| Zdroj: | Pulmonary Circulation Pulmonary Circulation, Vol 11 (2021) |
| ISSN: | 2045-8940 2045-8932 |
| Popis: | The implanted system for treprostinil has been described in previous publications. There is no information published about how to handle this system around lung or heart–lung transplantation. We present the experience from the DelIVery for Pulmonary Arterial Hypertension study. Seven subjects from five pulmonary arterial hypertension centers were included in this retrospective chart review. All subjects were participating in the previously described DelIVery for pulmonary arterial hypertension study. Seven subjects with implanted pumps have been listed for lung or heart–lung transplant. Six subjects underwent lung or heart–lung transplantation and one remains on the transplant list. Three different methods of patient management for transplant were used. In three subjects, the implanted system was filled with saline prior to transplantation and treprostinil was infused via an external system. Three subjects had their drug-filled implanted pump and catheter system explanted at the time of transplant. One patient had the drug-filled implanted system removed prior to being listed for transplantation. Four subjects were hospitalized while waiting for transplantation. In conclusion, the implanted system for treprostinil is an important advance in the care of pulmonary arterial hypertension subjects. The experience described here provides three effective strategies for managing the implanted system around lung or heart–lung transplantation. The optimal strategy will depend on patient characteristics and lung transplant program preferences and wait list times. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text